Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Receivables (2023 - 2025)

Historic Receivables for Krystal Biotech (KRYS) over the last 3 years, with Q3 2025 value amounting to $129.6 million.

  • Krystal Biotech's Receivables rose 3323.3% to $129.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.6 million, marking a year-over-year increase of 3323.3%. This contributed to the annual value of $104.7 million for FY2024, which is 14915.79% up from last year.
  • Latest data reveals that Krystal Biotech reported Receivables of $129.6 million as of Q3 2025, which was up 3323.3% from $111.4 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Receivables ranged from a high of $129.6 million in Q3 2025 and a low of $9.3 million during Q3 2023
  • Its 3-year average for Receivables is $89.5 million, with a median of $103.3 million in 2025.
  • Per our database at Business Quant, Krystal Biotech's Receivables skyrocketed by 94441.82% in 2024 and then tumbled by 138.05% in 2025.
  • Over the past 3 years, Krystal Biotech's Receivables (Quarter) stood at $42.0 million in 2023, then surged by 149.16% to $104.7 million in 2024, then increased by 23.76% to $129.6 million in 2025.
  • Its last three reported values are $129.6 million in Q3 2025, $111.4 million for Q2 2025, and $103.3 million during Q1 2025.